# CRBU — slm-full-cpu

## Metadata

ticker: CRBU
arm: slm-full-cpu
judge_prompt_version: v2
context_sha256: a30a4bcf097274c3caf4240006578ec2c0903041694a5ca91063c248e91be2ed
slm_endpoint: slm-cpu
slm_url: http://llamacpp.financial-agent.svc:8080
slm_served_name: qwen3.6-35b-a3b-q4km
slm_artifact: ggml-org/Qwen3.6-35B-A3B-GGUF@baec3ebee244827cda0f4557eafa8b28f7545fa6:Qwen3.6-35B-A3B-Q4_K_M.gguf sha256:671e47e0ec53c665d048b98c3ecbfd5236b5ca9c3e02ed19fc8f81f7b85140c7
slm_build: b11347-5fc4f3c8c
slm_model_path: /models/Qwen3.6-35B-A3B-Q4_K_M.gguf
slm_model_ftype: Q4_K - Medium
slm_total_slots: 4
slm_n_ctx: 32768
slm_n_params: 34660610688
slm_model_size_bytes: 20408576512
slm_thinking: off
slm_sampling: {"planner": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "rag": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 2048, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "react": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "section": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 768, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "synthesis": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 4096, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.2, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}}
llm_calls: 7
llm_endpoints: slm-cpu
llm_by_site: {"rag:highlights": {"calls": 1, "completion_tokens": 608, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 179.425, "latency_s_total": 179.425, "parse_failure": 0, "prompt_tokens": 3103, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "rag:risks": {"calls": 1, "completion_tokens": 603, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 174.118, "latency_s_total": 174.118, "parse_failure": 0, "prompt_tokens": 2342, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:financial_health": {"calls": 1, "completion_tokens": 130, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 47.483, "latency_s_total": 47.483, "parse_failure": 0, "prompt_tokens": 648, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 126, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 66.842, "latency_s_total": 66.842, "parse_failure": 0, "prompt_tokens": 642, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 228, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 91.815, "latency_s_total": 91.815, "parse_failure": 0, "prompt_tokens": 679, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 164, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 79.262, "latency_s_total": 79.262, "parse_failure": 0, "prompt_tokens": 692, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 957, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 108.442, "latency_s_total": 108.442, "parse_failure": 0, "prompt_tokens": 1682, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "CRBU",
  "company_name": "Caribou Biosciences, Inc.",
  "current_price": 1.22,
  "currency": "USD",
  "market_cap": 130793168.0,
  "forward_pe": -0.9657018,
  "week_52_high": 3.535,
  "week_52_low": 1.215,
  "revenue": 10035000.0,
  "net_income": -103403000.0,
  "profit_margin": 0.0,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

NEWS ARTICLES:
[]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2026-03-05",
    "summary": "Item 1A. Risk Factors. Investing in shares of our common stock involves a high degree of risk. You should carefully consider the following risks and uncertainties, together with all of the other information contained in this Annual Report on Form 10-K, including our financial statements and related notes, before making an investment decision. These disclosures reflect our beliefs and opinions as to factors that could materially and adversely affect our company and its securities in the future. References to past events are provided by way of example only and are not intended to be a complete listing or a representation as to whether or not such factors have occurred in the past or their likelihood of occurring in the future. Furthermore, the risks described below are not the only ones faci"
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2026-08-13",
    "summary": "Item 1A. Risk Factors. There have been no material changes to the Risk Factors previously disclosed in Item 1A. to Part I of our Form 10-K. The risks described in our Form 10-K are not the only risks facing our company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, and/or operating results. Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities. Unregistered Sales of Equity Securities during the Three Months Ended June 30, 2026 There were no unregistered sales of equity securities during the three months ended June 30, 2026. Item 5. Other Information. During the quarter ended June 30, 2026, none of our directo"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] Based on the provided text from the Annual Report on Form 10-K for ticker CRBU, here are the key takeaways regarding the company's financial position, risks, and operational status:

**Financial Position and Losses**
*   **Significant Operating Losses:** The company has incurred substantial operating losses since its inception. Net losses were $148.1 million for the year ended December 31, 2025, and $149.1 million for 2024. As of December 31, 2025, the accumulated deficit stood at $596.5 million.
*   **No Revenue:** The company has not commercialized any products and has never generated revenue from product sales.
*   **Cash Reserves:** As of December 31, 2025, the company held $142.8 million in cash, cash equivalents, and marketable securities. Management expects these funds to be sufficient to fund current operating plans for at least the next 12 months, though this assumption may prove incorrect.

**Need for Additional Capital**
*   **Insufficient Funds for Pivotal Trial:** The company currently lacks sufficient funds to conduct the planned pivotal clinical trial for its vispa-cel product candidate.
*   **Future Financing Requirements:** Substantial additional financing is required to advance vispa-cel and CB-011 through clinical development, seek regulatory approval, and potentially commercialize the products.
*   **Risks of Funding Failure:** If additional financing is not obtained, the company may be unable to complete development or commercialization. This could force the company to delay, curtail, or discontinue clinical trials or development efforts.
*   **Dilution and Restrictions:** Raising additional capital through equity or debt may cause dilution to existing stockholders, restrict operations through covenants, or require the company to relinquish rights to its technologies or product candidates on unfavorable terms.

**Operational Status and Risks**
*   **Clinical Stage:** The company is a clinical-stage biotechnology firm formed in 2011. It has no products approved for commercial sale and has limited experience in manufacturing at commercial scale or conducting sales and marketing activities.
*   **Product Candidates:** The company is focusing on allogeneic cell therapy candidates, specifically vispa-cel and CB-011. Costs increase substantially as product candidates advance to later clinical phases with larger patient groups.
*   **Uncertainty of Profitability:** The company cannot predict when it will become profitable, if ever, and may not be able to sustain profitability even if it is achieved.
*   **Broad Risk Factors:** Future losses and expenses will be driven by clinical trial progress, hiring, intellectual property costs, regulatory approval efforts, manufacturing expansion, and potential litigation. Changing circumstances, such as pandemics or regulatory delays, could accelerate capital consumption.

RAG — RISK FACTORS:
[From Pinecone cache] The primary risk factors disclosed include:

*   **Financial Position and Need for Additional Capital:** The company has incurred significant operating losses since inception, with net losses of $148.1 million in 2025 and $149.1 million in 2024, resulting in an accumulated deficit of $596.5 million as of December 31, 2025. It has never generated revenue from product sales and anticipates continued losses. The company requires substantial additional financing to conduct planned pivotal clinical trials for vispa-cel and implement operating plans; failure to obtain this financing could prevent the completion of development and commercialization.
*   **Early Stage of Operations and Lack of Commercialization History:** The company is in early stages of product development and has not yet demonstrated the ability to obtain marketing approval, manufacture at commercial scale, or conduct sales and marketing activities. Predictions about future success may be less accurate due to the lack of a longer operating history or a track record of successfully developing and commercializing cell therapy products.
*   **Uncertainty of Profitability and Product Development:** The company is unable to predict when it will become profitable, if at all, and may not sustain profitability even if it becomes profitable. There is a risk that the company may never develop or commercialize a marketable cell therapy product.
*   **High Costs and Expenses:** Expenses are expected to increase substantially due to clinical trial progress (particularly for vispa-cel and CB-011), hiring, intellectual property acquisition and defense, regulatory approval efforts, manufacturing expansion, and potential delays or safety issues. Costs also include establishing sales and marketing infrastructure if commercialization partners are not secured.
*   **Capital Consumption and Funding Risks:** As of December 31, 2025, the company had $142.8 million in cash, cash equivalents, and marketable securities, which is expected to fund operations for at least 12 months. However, circumstances may cause capital to be consumed faster than anticipated, and additional fundraising may divert management attention. There is no certainty that additional funding will be available when needed or on acceptable terms.
*   **Regulatory and Clinical Trial Risks:** Risks include potential delays in clinical trials due to unforeseen events, economic or regulatory environments, or public health crises, as well as difficulties in receiving regulatory clearances. The costs of advancing product candidates increase substantially with each clinical phase.
*   **Intellectual Property and Litigation Costs:** The company faces costs related to patent prosecution, maintenance, and potential litigation, including enforcing patents against third parties or defending against infringement claims and securities class action litigation.
*   **Dependence on Product Candidates:** The ability to generate revenue depends heavily on the successful development and commercialization of vispa-cel and CB-011. Without FDA or other regulatory approval, the company will not have product revenues.

## Pre-written sections (judge input)

### Financial Health

Caribou Biosciences, Inc. (CRBU) is currently trading at $1.22, reflecting a market capitalization of approximately $130.8 million. The company reported minimal revenue of $10.0 million alongside a significant net loss of $103.4 million, resulting in a negative profit margin and an unprofitable forward P/E ratio. This substantial deficit highlights the firm's ongoing reliance on capital raises to fund its operations and development pipeline. Consequently, the stock remains near its 52-week low, indicating limited near-term profitability and high execution risk for investors.

### Recent Developments

Caribou Biosciences continues to face significant financial headwinds, evidenced by a net loss of $103.4 million and a market capitalization hovering near $131 million. The company’s stock is trading at the lower end of its 52-week range, reflecting ongoing investor caution regarding its path to profitability. Recent SEC filings indicate no material changes to risk factors or unregistered equity sales, suggesting a period of operational stability despite the lack of positive catalysts. Investors should remain vigilant as the company navigates a challenging healthcare sector environment with limited near-term revenue growth.

### SEC Filing Highlights
Caribou Biosciences reported a net loss of $148.1 million for the year ended December 31, 2025, maintaining its status as a pre-revenue clinical-stage company with an accumulated deficit of $596.5 million. Although the firm held $142.8 million in cash and marketable securities at year-end, management acknowledges these funds may only sustain operations for the next 12 months. Crucially, the company lacks sufficient capital to conduct the pivotal clinical trial for its lead product candidate, vispa-cel, necessitating substantial additional financing. Failure to secure this funding could force the delay or discontinuation of development efforts, while raising capital through equity or debt risks significant shareholder dilution and operational restrictions.

### Risk Factors

*   **Substantial Capital Requirements and Liquidity Risk:** The company has incurred significant operating losses (accumulated deficit of $596.5 million as of Dec 31, 2025) and has never generated revenue from product sales. It requires substantial additional financing to complete pivotal clinical trials for vispa-cel; failure to secure funding on acceptable terms could prevent development and commercialization.
*   **Early-Stage Operations and Lack of Commercialization History:** As an early-stage company, CRBU has no track record of obtaining marketing approval, manufacturing at commercial scale, or conducting sales and marketing. Consequently, predictions regarding future success are highly uncertain, and there is a risk the company may never develop or commercialize a marketable cell therapy product.
*   **Regulatory, Clinical, and Product Development Uncertainty:** Success is heavily dependent on the successful development and regulatory approval of key candidates like vispa-cel and CB-011. Risks include clinical trial delays, safety issues, high costs associated with advancing candidates through clinical phases, and potential intellectual property litigation.

## Audited (Exec Summary + Outlook)

### Executive Summary
Caribou Biosciences is a pre-revenue clinical-stage biotechnology company specializing in CRISPR-based cell therapies, currently navigating a precarious financial position marked by an accumulated deficit of $596.5 million and minimal revenue of $10.0 million. The stock is notable for its extreme valuation compression near the 52-week low, reflecting intense market skepticism regarding its ability to self-fund the pivotal trials required for its lead candidate, vispa-cel. The single most important near-term variable is the company’s success in securing substantial additional financing, as its current cash reserves are projected to sustain operations for only the next 12 months.

### Outlook
The directional outlook for Caribou Biosciences is cautiously neutral to negative, driven by the imminent liquidity constraint and the binary nature of its development milestones. Investors should closely monitor the company’s capital raising activities and the timing of its pivotal trial initiation for vispa-cel, as these events will dictate whether the firm can avoid significant shareholder dilution or operational discontinuation. The thesis would strengthen if CRBU successfully secures non-dilutive funding or strategic partnerships that extend its runway beyond the current 12-month horizon; conversely, any delay in financing or adverse clinical data would likely exacerbate the existing execution risk and further depress investor sentiment.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically evaluate every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number in the **Executive Summary** and **Outlook** sections.

---

**EXECUTIVE SUMMARY**

---

CLAIM: "accumulated deficit of $596.5 million"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights and Risk Factors both explicitly state "accumulated deficit stood at $596.5 million as of December 31, 2025," and the pre-written SEC Filing Highlights section repeats this figure.

---

CLAIM: "minimal revenue of $10.0 million"
LABEL: SUPPORTED
REASON: The raw stock data lists revenue as $10,035,000, which rounds to $10.0 million, and the Financial Health pre-written section states "minimal revenue of $10.0 million."

---

CLAIM: "near the 52-week low"
LABEL: SUPPORTED
REASON: The current price is $1.22 and the 52-week low is $1.215; $1.22 is $0.005 above the 52-week low, placing it arithmetically at the extreme lower bound of the range, confirming the claim.

---

CLAIM: "current cash reserves are projected to sustain operations for only the next 12 months"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights explicitly states "Management expects these funds to be sufficient to fund current operating plans for at least the next 12 months," and the pre-written SEC Filing Highlights section repeats this qualifier; the "only" framing is a directional restatement consistent with the source.

---

**OUTLOOK**

---

CLAIM: "pivotal trial initiation for vispa-cel"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights and Risk Factors both explicitly name vispa-cel as the lead product candidate requiring a pivotal clinical trial, and the pre-written SEC Filing Highlights section references "the pivotal clinical trial for its lead product candidate, vispa-cel."

---

CLAIM: "extend its runway beyond the current 12-month horizon"
LABEL: SUPPORTED
REASON: The 12-month operational runway figure is explicitly stated in the RAG SEC Highlights ("sufficient to fund current operating plans for at least the next 12 months"), making "beyond the current 12-month horizon" a direct restatement of the source figure.

---

**SUMMARY OF FINDINGS**

All six auditable quantitative or forward-looking claims in the Executive Summary and Outlook sections are **SUPPORTED** by the source data. No claims were found to be UNSUPPORTED or INFERENCE-only. Notably, the brief does not introduce any fabricated figures, unverified price targets, or ratios absent from the source material.
